BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Epocal Inc. Completes $31 Million Series C Financing


4/11/2007 11:03:57 AM

OTTAWA, April 10 /PRNewswire/ - Epocal, a privately held developer of enterprise point-of-care blood diagnostic products, announces the closing of a US$31 million Series C equity financing.

The Series C round was led by Highland Capital Management L.P. of Dallas, Texas and also included participation from founding investor, Genesys Capital Partners. Proceeds of the financing will be used to commercialize EPOC(TM), the Company's FDA 510 (k) approved blood diagnostic platform, as well as develop its proprietary immunoassay technology.

Epocal CEO Dr. Imants Lauks stated that "we are very excited to have a strong financial partner like Highland Capital Management join our investor group, and we are pleased to welcome Mr. Nathan Hukill of Highland Capital Management who joins Epocal's board of directors with the closing of this transaction."

Aquilo Partners Inc., a life science investment bank, was the exclusive placement agent for the transaction.

About Epocal

The EPOC(TM) System, the Company's enterprise point-of-care blood analysis platform combines ultra-low cost, smart-card like diagnostic cards containing biosensors and fluidics-on-flex circuits with ultra-low cost bedside card readers. The readers communicate wirelessly to a mobile handheld computer or PDA for immediate bedside results and to a portal on a hospital network for centralized data management. The platform delivers lab quality results to the bedside at a significantly lower manufacturing cost of conventional point-of- care testing solutions. The product development pipeline includes cards for a variety of test applications including immunoassay biomarker tests, general chemistries, hematology and hemostasis.

About Highland Capital Management L.P.

Based in Dallas, Texas, with offices in New York and London, Highland Capital Management, L.P. is a SEC-registered investment adviser specializing in credit and alternative investment investing. Highland Capital currently manages US$35 billion in leveraged loans, high yield bonds, structured products and other assets for banks, insurance companies, pension plans, foundations, and high net worth individuals.

EPOCAL INC.

CONTACT: Joyce Wilson, (613) 738-6192, ext. 224, jwilson@epocal.com;www.epocal.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES